Michael Ong, MD
Internal Medicine · Vandergrift, PANPI 1639162969
Payments from drug & device makers
Across 893 payments — averaging $14.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- GSK$2K
- Pfizer$1K
- AstraZeneca$1K
- Amgen$994
- Johnson & Johnson$823
- plus $4K from 28 others
What the payments were for
- Food & beverage$12,64499%
- Education$661%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 218 | $2,400 |
| GSK | 115 | $1,772 |
| Pfizer | 88 | $1,249 |
| AstraZeneca | 60 | $1,055 |
| Amgen(2 entities) | 71 | $994 |
| Johnson & Johnson | 45 | $823 |
| Lilly USA, LLC | 46 | $684 |
| Boehringer Ingelheim | 44 | $608 |
| Novartis | 30 | $535 |
| Daiichi Sankyo Inc. | 34 | $405 |
| Merck | 23 | $345 |
| AbbVie(2 entities) | 11 | $215 |
| Kowa Pharmaceuticals America, Inc. | 14 | $213 |
| Bayer | 14 | $209 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $189 |
| Ironwood Pharmaceuticals, Inc | 12 | $175 |
| Amarin Pharma, Inc. | 9 | $136 |
| E.r. Squibb & Sons, L.L.C. | 9 | $126 |
| Dexcom, Inc. | 6 | $96 |
| Astellas Pharma US Inc | 4 | $64 |
| Currax Pharmaceuticals LLC | 4 | $60 |
| Grifols USA, LLC | 3 | $56 |
| Sunovion Pharmaceuticals Inc. | 4 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $32 |
| Otsuka America Pharmaceutical, Inc. | 2 | $30 |
| Exact Sciences | 2 | $30 |
| Hikma Pharmaceuticals USA | 2 | $29 |
| Sanofi-aventis U.S. LLC | 2 | $25 |
| Cequr Corporation | 2 | $19 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Abbott | 1 | $17 |
| Theracosbio, LLC | 1 | $16 |
| Redhill Biopharma Inc. | 1 | $13 |
How this compares
$12,710 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 234 | $221,547 |
| OzempicSemaglutide | 149 | $178,223 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 161 | $134,729 |
| MounjaroTirzepatide | 99 | $134,099 |
| XareltoRivaroxaban | 114 | $98,500 |
| JardianceEmpagliflozin | 101 | $90,080 |
| TrulicityDulaglutide | 82 | $88,416 |
| FarxigaDapagliflozin Propanediol | 36 | $46,288 |
| GlyxambiEmpagliflozin/Linagliptin | 48 | $45,620 |
| ProliaDenosumab | 23 | $39,288 |
| MyrbetriqMirabegron | 56 | $39,155 |
| Breo ElliptaFluticasone/Vilanterol | 71 | $37,618 |
| RybelsusSemaglutide | 23 | $34,131 |
| JanuviaSitagliptin Phosphate | 38 | $30,159 |
| TradjentaLinagliptin | 42 | $27,257 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $684 | $222,515181 claims |
| PfizerEliquis | $1,249 | $221,547234 claims |
| Novo NordiskOzempic, Rybelsus | $2,400 | $212,354172 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,772 | $172,347232 claims |
| Boehringer IngelheimJardiance, Glyxambi, Tradjenta | $608 | $162,957191 claims |
| Johnson & JohnsonXarelto | $823 | $98,500114 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,055 | $67,86465 claims |
| MerckJanuvia, Janumet | $345 | $43,05759 claims |
| AmgenProlia | $994 | $39,28823 claims |
| Astellas Pharma US IncMyrbetriq | $64 | $39,15556 claims |
| NovartisEntresto | $535 | $23,27815 claims |
| AbbVieLinzess | $215 | $17,92827 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Vandergrift
- Jonathan EpsteinPhiladelphia$13.1M
- Siddharth ShethPittsburgh$11M
- Nathan PatelTannersville$9.5M
- Pitamber DevgonPhiladelphia$7.5M
- Christopher StillDanville$7.1M
- Liza VillaruzPittsburgh$6.6M
- Paul HartleyUniontown$4.9M
- Victor KoladeSayre$4.7M
- Michael OliverBeaver$4.7M
- Raman PurighallaPittsburgh$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.